NYSE:RCUS Arcus Biosciences (RCUS) Stock Price, News & Analysis → This company has increased its dividend every year for 54 years (From DTI) (Ad) Free RCUS Stock Alerts $14.83 -1.04 (-6.55%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$14.80▼$16.0450-Day Range$14.82▼$20.1852-Week Range$12.95▼$25.47Volume791,278 shsAverage Volume819,959 shsMarket Capitalization$1.35 billionP/E RatioN/ADividend YieldN/APrice Target$41.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Arcus Biosciences alerts: Email Address Arcus Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside177.8% Upside$41.25 Price TargetShort InterestBearish17.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$320 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.15 out of 5 starsMedical Sector770th out of 914 stocksPharmaceutical Preparations Industry342nd out of 412 stocks 3.4 Analyst's Opinion Consensus RatingArcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageArcus Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.43% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Arcus Biosciences has recently increased by 3.38%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RCUS. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 4 people have searched for RCUS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have bought 31,433.96% more of their company's stock than they have sold. Specifically, they have bought $319,999,995.00 in company stock and sold $1,014,779.00 in company stock.Percentage Held by Insiders13.80% of the stock of Arcus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arcus Biosciences are expected to remain at ($3.59) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIStart loving Mondays like thisWouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!Weekend after weekend! About Arcus Biosciences Stock (NYSE:RCUS)Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Read More RCUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCUS Stock News HeadlinesMarch 30, 2024 | insidertrades.comInsider Selling: Arcus Biosciences, Inc. (NYSE:RCUS) COO Sells 11,551 Shares of StockMarch 21, 2024 | insidertrades.comInsider Selling: Arcus Biosciences, Inc. (NYSE:RCUS) COO Sells 13,449 Shares of StockApril 17, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 9, 2024 | businesswire.comArcus Biosciences Announces New Employment Inducement GrantsApril 1, 2024 | finance.yahoo.comInvestors bid Arcus Biosciences (NYSE:RCUS) up US$219m despite increasing losses YoY, taking five-year CAGR to 8.1%March 29, 2024 | finance.yahoo.comInsider Sell: COO Jennifer Jarrett Sells 11,551 Shares of Arcus Biosciences Inc (RCUS)March 29, 2024 | msn.comXilio and Gilead partner up for IL-12 therapeutic developmentMarch 26, 2024 | businesswire.comArcus Biosciences Announces New Employment Inducement GrantsApril 17, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.March 25, 2024 | markets.businessinsider.comNavigating 5 Analyst Ratings For Arcus BiosciencesMarch 22, 2024 | investing.comArcus Biosciences COO sells over $240k in company stockMarch 20, 2024 | finance.yahoo.comInsider Sell: COO Jennifer Jarrett Sells 13,449 Shares of Arcus Biosciences Inc (RCUS)March 11, 2024 | businesswire.comArcus Biosciences Announces New Employment Inducement GrantsFebruary 29, 2024 | finance.yahoo.comInsider Sell: COO Jennifer Jarrett Sells 58,625 Shares of Arcus Biosciences Inc (RCUS)February 28, 2024 | businesswire.comArcus Biosciences to Participate in Two Upcoming Investor ConferencesFebruary 27, 2024 | businesswire.comArcus Biosciences Announces New Employment Inducement GrantsFebruary 26, 2024 | markets.businessinsider.comEvaluating Arcus Biosciences’ Casdatifan Potential and Strategic Position in RCC Treatment LandscapeFebruary 22, 2024 | msn.comGilead downgraded at Truist on cancer strategyFebruary 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Ionis Pharmaceuticals (IONS) and Icon (ICLR)February 22, 2024 | finance.yahoo.comArcus Biosciences, Inc. (NYSE:RCUS) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | seekingalpha.comArcus Biosciences: Trading At Large Discount To Recent Gilead InvestmentFebruary 21, 2024 | msn.comArcus Biosciences GAAP EPS of -$1.08 misses by $0.06, revenue of $31M beats by $2.7MFebruary 21, 2024 | finance.yahoo.comArcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline UpdateFebruary 21, 2024 | businesswire.comArcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline UpdateFebruary 18, 2024 | finance.yahoo.comRCUS Mar 2024 30.000 callFebruary 18, 2024 | finance.yahoo.comRCUS Mar 2024 20.000 putFebruary 17, 2024 | ca.finance.yahoo.comRCUS Mar 2024 10.000 callSee More Headlines Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today4/17/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:RCUS CUSIPN/A CIK1724521 Webwww.arcusbio.com Phone(510) 694-6200FaxN/AEmployees577Year FoundedN/APrice Target and Rating Average Stock Price Target$41.25 High Stock Price Target$70.00 Low Stock Price Target$23.00 Potential Upside/Downside+160.3%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-307,000,000.00 Net Margins-262.39% Pretax Margin-257.27% Return on Equity-57.17% Return on Assets-25.80% Debt Debt-to-Equity RatioN/A Current Ratio4.52 Quick Ratio4.52 Sales & Book Value Annual Sales$117 million Price / Sales12.31 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book2.57Miscellaneous Outstanding Shares90,860,000Free Float78,326,000Market Cap$1.44 billion OptionableOptionable Beta0.81 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Terry J. Rosen Ph.D. (Age 64)Co-Founder, Chairman & CEO Comp: $756.11kDr. Juan Carlos Jaen Ph.D. (Age 66)Co- Founder & President Comp: $931.14kMr. Robert C. Goeltz II (Age 51)Principal Financial Officer & CFO Comp: $745.29kMs. Jennifer A. Jarrett M.B.A. (Age 53)Chief Operating Officer Comp: $925.29kDr. Dimitry S.A. Nuyten M.D. (Age 48)Ph.D., Chief Medical Officer Comp: $700.34kDr. K. Christopher Garcia Ph.D.Co-Founder & Member of Scientific Advisory BoardMr. Alexander Azoy (Age 48)VP of Finance & Principal Accounting Officer Dr. Jonathan Yingling Ph.D. (Age 55)Chief Scientific Officer More ExecutivesKey CompetitorsZai LabNASDAQ:ZLABKura OncologyNASDAQ:KURALigand PharmaceuticalsNASDAQ:LGNDMorphicNASDAQ:MORFANI PharmaceuticalsNASDAQ:ANIPView All CompetitorsInsiders & InstitutionsGAMMA Investing LLCBought 826 shares on 4/5/2024Ownership: 0.003%Jennifer JarrettSold 11,551 sharesTotal: $202,720.05 ($17.55/share)PNC Financial Services Group Inc.Sold 2,394 shares on 3/22/2024Ownership: 0.002%Jennifer JarrettSold 13,449 sharesTotal: $241,006.08 ($17.92/share)Vanguard Group Inc.Bought 186,898 shares on 3/11/2024Ownership: 5.152%View All Insider TransactionsView All Institutional Transactions RCUS Stock Analysis - Frequently Asked Questions Should I buy or sell Arcus Biosciences stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RCUS shares. View RCUS analyst ratings or view top-rated stocks. What is Arcus Biosciences' stock price target for 2024? 8 analysts have issued 12-month target prices for Arcus Biosciences' shares. Their RCUS share price targets range from $23.00 to $70.00. On average, they expect the company's stock price to reach $41.25 in the next year. This suggests a possible upside of 177.8% from the stock's current price. View analysts price targets for RCUS or view top-rated stocks among Wall Street analysts. How have RCUS shares performed in 2024? Arcus Biosciences' stock was trading at $19.10 at the beginning of 2024. Since then, RCUS stock has decreased by 22.3% and is now trading at $14.85. View the best growth stocks for 2024 here. When is Arcus Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RCUS earnings forecast. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences, Inc. (NYSE:RCUS) posted its quarterly earnings results on Wednesday, February, 21st. The company reported ($1.08) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.01. The business had revenue of $31 million for the quarter, compared to analyst estimates of $28.30 million. Arcus Biosciences had a negative net margin of 262.39% and a negative trailing twelve-month return on equity of 57.17%. The business's quarterly revenue was down 8.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.93) earnings per share. What ETFs hold Arcus Biosciences' stock? ETFs with the largest weight of Arcus Biosciences (NYSE:RCUS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Range Cancer Therapeutics ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco S&P SmallCap Health Care ETF (PSCH). What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO? 4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD). When did Arcus Biosciences IPO? Arcus Biosciences (RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO. Who are Arcus Biosciences' major shareholders? Arcus Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include GAMMA Investing LLC (0.00%). Insiders that own company stock include Alexander Azoy, Carolyn C Tang, Carolyn C Tang, Gilead Sciences, Inc, Jennifer Jarrett, Juan C Jaen, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko. View institutional ownership trends. How do I buy shares of Arcus Biosciences? Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:RCUS) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchYour Money is Not SafeAmerican AlternativeOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.